A randomised phase II study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease

See ANZCTR for full trial details >

 

Trial Summary:

The five year overall survival for patients with pancreatic cancer is 8%. Pancreatic Cancer also has the fifth highest incidence of cancer related mortality and accounts for the death of more than 2,900 Australians annually.

MASTERPLAN investigates whether SBRT in addition to modern chemotherapy is superior to the current standard of chemotherapy alone in both the neoadjuvant and definitive setting. An important component of MASTERPLAN is to incorporate high quality tissue collection to facilitate future molecular and genetic research.

Stereotactic body radiotherapy (SBRT) is a highly innovative treatment that utilises the significant technological advancements in radiotherapy treatment. SBRT enables safe radiotherapy dose escalation that increases tumour cell death, while minimising dose and toxicity to surrounding normal tissues.

Supported By:

AGITG

Eligibility:

Adults, aged between 18-75 years, with histological confirmation of pancreatic adenocarcinoma.

 Registration ID:  ACTRN12619000409178

Participation:

ANZ

Australian Lead Group:

AGITG

Status:

Open

Chairs:

Dr Andrew Oar
A/Prof Andrew Kneebone

Activation Date:

2019

Contact:

MASTERPLAN.study@sydney.edu.au